Cargando…
Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289147/ https://www.ncbi.nlm.nih.gov/pubmed/37361211 http://dx.doi.org/10.3389/fphar.2023.1222209 |
| _version_ | 1785062213257527296 |
|---|---|
| author | Wang, Zhi-Bin Liu, Dan Lei, Guang Liu, Zhao-Qian Wu, Nayiyuan Wang, Jing |
| author_facet | Wang, Zhi-Bin Liu, Dan Lei, Guang Liu, Zhao-Qian Wu, Nayiyuan Wang, Jing |
| author_sort | Wang, Zhi-Bin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10289147 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102891472023-06-24 Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more Wang, Zhi-Bin Liu, Dan Lei, Guang Liu, Zhao-Qian Wu, Nayiyuan Wang, Jing Front Pharmacol Pharmacology Frontiers Media S.A. 2023-06-09 /pmc/articles/PMC10289147/ /pubmed/37361211 http://dx.doi.org/10.3389/fphar.2023.1222209 Text en Copyright © 2023 Wang, Liu, Lei, Liu, Wu and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Pharmacology Wang, Zhi-Bin Liu, Dan Lei, Guang Liu, Zhao-Qian Wu, Nayiyuan Wang, Jing Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more |
| title | Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more |
| title_full | Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more |
| title_fullStr | Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more |
| title_full_unstemmed | Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more |
| title_short | Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more |
| title_sort | editorial: ovarian cancer-targeted medication: parp inhibitors, anti-angiogenic drugs, immunotherapy, and more |
| topic | Pharmacology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289147/ https://www.ncbi.nlm.nih.gov/pubmed/37361211 http://dx.doi.org/10.3389/fphar.2023.1222209 |
| work_keys_str_mv | AT wangzhibin editorialovariancancertargetedmedicationparpinhibitorsantiangiogenicdrugsimmunotherapyandmore AT liudan editorialovariancancertargetedmedicationparpinhibitorsantiangiogenicdrugsimmunotherapyandmore AT leiguang editorialovariancancertargetedmedicationparpinhibitorsantiangiogenicdrugsimmunotherapyandmore AT liuzhaoqian editorialovariancancertargetedmedicationparpinhibitorsantiangiogenicdrugsimmunotherapyandmore AT wunayiyuan editorialovariancancertargetedmedicationparpinhibitorsantiangiogenicdrugsimmunotherapyandmore AT wangjing editorialovariancancertargetedmedicationparpinhibitorsantiangiogenicdrugsimmunotherapyandmore |